国产精品又长又粗又爽又黄的毛片, 国产AV无码专区亚洲AV毛片搜, 丰满人妻被猛烈进入中文字幕四川, 国产精品一区二区三区国产女人喷,亚洲国产欧美日韩图片在线人,潘娇娇337p人艺体艺术,成人免费无码大片a毛片古装,一本到高清视频免费,人妻在线视频免费看

400-885-9898
更新于 2月13日
智聯(lián)APPAPP
舉報

體內(nèi)藥理高級研究員(J10740)

2-4萬
  • 北京昌平區(qū)
  • 3-5年
  • 博士
  • 全職
  • 招1人

職位描述

藥效學研究腫瘤藥物動物疾病模型
崗位職責:
1.Independently develop and optimize in-vivo animal models critical for the screening of therapeutic small molecules, antibodies, ADCs, multi-specific biologics including TCE, and other biological molecules with complex structures;
2.Perform troubleshooting and optimization experiments; prepare technical report and presentation as needed;
3.Provides scientific perspective and leadership to research programs. A primary focus and experience in either oncology research or auto-immune disease therapeutic areas is preferred;
4.Works with program teams to set objectives, timeline, deliverables and manage multiple programs;
5.Responsible for data review, analysis, and interpretation from a variety of sources and evaluates the impact on program deliverables. Provides input into go/no-go decisions for programs
任職要求:
1.Ph.D. degree in biology, cancer biology or immunology background will be preferred;
2.3+ years of experience in preclinical research, ideally within the small molecule/biologics oncology/inflammation setting. Proven drug discovery and development experience is preferred;
3.Experience with one or both of the following skill sets is required: 1): in vivo pharmacology models for Immuno-oncology/Immunotherapy including humanized reconstitution animal models for immune checkpoint inhibitors (ICI), multi-specific biologics (including multi-ICI, TCE) and other and other novel/complex modalities; 2): Autoimmune disease animal models such as IBD, EAE, atopic dermatitis, asthma, PsO, GvHD, SLE, delayed type hypersensitivity, kidney disease, etc.
4.Ability to independently analyze and interpret data and provide scientific approaches. Be able to write technical documents independently; Familiar with FDA/NMPA IND submission package, experience in IND submit is preferred;
5.Highly organized and collaborative individual with an ability to work in a fast-paced work environment and to handle multiple projects;
6.Strong written and communication skills with good literature reading capability; and an ability to work effectively with a diverse team of co-workers in a dynamic environment;
7.The ideal candidate will be diligent, self-motivated, detail-oriented, highly organized, and able to adapt quickly to changes.

工作地點

昌平區(qū)北京諾誠健華醫(yī)藥科技有限公司

認證資質(zhì)

營業(yè)執(zhí)照信息

職位發(fā)布者

婁女士/HR

三日內(nèi)活躍
立即溝通
公司Logo諾誠健華
諾誠健華（上交所代碼：688428；香港聯(lián)交所代碼：09969）于2015年由世界著名結(jié)構(gòu)生物學家施一公院士和生物醫(yī)藥行業(yè)卓越的科學家兼企業(yè)家崔霽松博士聯(lián)合創(chuàng)立。作為一家植根于中國且具有全球視野的新藥創(chuàng)制公司，諾誠健華以“科學驅(qū)動創(chuàng)新患者所需為本”為價值理念，專注于惡性腫瘤和自身免疫性疾病的創(chuàng)新藥研究和開發(fā)。經(jīng)過近十年的堅實發(fā)展，公司在各方面取得重大進展。2020年3月23日，諾誠健華成功在港交所上市，成為2020年港交所生物醫(yī)藥第*一股。2022年9月21日，諾誠健華在上海證券交易所科創(chuàng)板上市，開啟了H+A的新征程。目前，諾誠健華已經(jīng)打造了具有市場前景的強大產(chǎn)品管線，覆蓋血液瘤、實體瘤和自身免疫性疾病。諾誠健華自主研發(fā)的國家“重大新藥創(chuàng)制”專項成果——BTK抑制劑奧布替尼（商品名：宜諾凱?）目前已在中國和新加坡獲批上市并納入中國國家醫(yī)保，是中國首*個且唯*一獲批針對邊緣區(qū)淋巴瘤的BTK抑制劑；坦昔妥單抗（商品名：明諾凱?）創(chuàng)新療法已成為中國首*個獲批治療復發(fā)/難治性彌漫性大B細胞淋巴瘤（R/R DLBCL）的CD19單抗；mesutoclax（ICP-248）是中國第*一個獲得突破性療法認定（Breakthrough Therapy Designation）的BCL2抑制劑，10多款創(chuàng)新藥在臨床階段。諾誠健華已經(jīng)構(gòu)建了從源頭創(chuàng)新、臨床開發(fā)、生產(chǎn)到商業(yè)化的全產(chǎn)業(yè)鏈平臺。在具有豐富研發(fā)、生產(chǎn)和商業(yè)化經(jīng)驗的管理團隊的帶領(lǐng)下，諾誠健華已構(gòu)建起一體化的生物醫(yī)藥平臺，包括藥物晶型研究平臺、難溶性藥物增溶制劑技術(shù)研發(fā)及產(chǎn)業(yè)化平臺、生物大分子發(fā)現(xiàn)和工程化改造平臺等，加速為全球腫瘤和自身免疫性疾病患者開發(fā)并提供極具市場前景的創(chuàng)新療法。發(fā)展至今，諾誠健華現(xiàn)有員工1200多人，眾多員工擁有海外工作和世界500*強藥企工作經(jīng)驗，并擁有多名國家*級、省市級人才專家。諾誠健華在北京、南京、上海、廣州、香港和美國等多地均設(shè)有分支機構(gòu)。
公司主頁